NGNE (Neurogene Therapeutics) Market Value to Book Value Ratio
Neurogene Inc. (NGNE) focuses on developing precise gene correction methods, utilizing a patent-protected gene activity control system to ensure brain safety. The company's resources are concentrated on early-stage development, which creates high risks regarding test outcomes. The available price action vector on GURU.Markets is 1.98. Financial success is based on selling high-cost therapy courses for rare pathologies to insurance companies.
%20Capitalization%20to%20Book%20Value%20Ratio&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_NGNE_-_Neurogene-Inc._-_Capitalization-to-Book-Value-Ratio "NGNE Neurogene Market Capitalization to Book Value Ratio (02/21/2024 - 10/28/2026) | 👁️GURU.Markets👁️")
Financial and market metric breakdowns for Neurogene Inc (NGNE)
- price and consensus price forecast:
- market capitalization data:
- book capitalization data:
- debt and liquidity data:
Fundamental valuation:NGNE, Neurogene Inc.
The stability of the US legal framework and the humanitarian status of Neurogene Inc. (NGNE) developments make the current market value-to-book value ratio a key indicator of market confidence in its intellectual capital. By dividing market value by net assets, an investor determines the growth premium; a significant upward deviation signals that the company is overvalued relative to its book value.
Competitor analysis
Market Capitalization to Book Value Ratio BIIB|NBIX (neurocrine.com) - Market-to-Book Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|ACADIA Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Xenon Corp XENE|Market Cap to Net Assets Ratio VKTX (Viking Therapeutics)|supernus.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Catalyst Pharmaceuticals, Inc. (CPRX)|DNLI: Market Value to Book Value|Market Value to Book Value Ratio HRMY|BHVN (Biohaven Corp) - Market-to-Book Ratio|Market Value to Book Value Ratio Amylyx Pharmaceuticals (AMLX)|Capitalization to Book Value Ratio trevitherapeutics.com|Praxis Precision Medicines, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Anavex AVXL|Market Cap to Net Assets Ratio CBLL (CeriBell Corp)|Prothena - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Alector Therapeutics (ALEC)|ANNX: Market Value to Book Value|Market Value to Book Value Ratio OMER|AC Immune S.A. (ACIU) - Market-to-Book Ratio|Voyager Pharma - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio Neumora Corp|Scilex Holding Company - Market Capitalization to Book Value Ratio|Market-to-Book Ratio TVGN (tevogen.com)|ACOG - Market Value to Book Value Ratio|Capitalization to Book Value Ratio cogrx.com CGTX|IKT (Inhibikase) - Market Capitalization to Book Value Ratio|Cassava Pharma (SAVA) - Market-to-Book Ratio|Market Cap to Net Assets Ratio assertiotx.com ASRT|Coya Therapeutics (COYA) - Market Value to Book Value|VTGN: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value OVID|Market Value to Book Value Ratio Acumen Pharma ABOS|Capitalization to Book Value Ratio CervoMed Corporation (CRVO)|Alterity Therapeutics Limited - Market Capitalization to Book Value Ratio|CLNN - Market Cap to Net Assets Ratio|Market Cap to Net Assets Ratio PEPG (PepGen Corp)|JUNS: Market Capitalization to Book Value|Market Value to Book Value Ratio Relmada|Annovis Bio Corporation (ANVS) - Capitalization to Book Value Ratio|Grace Therapeutics Inc - Market Capitalization to Book Value Ratio|Market Value to Equity Ratio AIFF|Market Value to Book Value Ratio Klotho Neurosciences Inc KLTO|Capitalization to Book Value Ratio neurosense-tx.com (NRSN)|RVPH: Market Capitalization to Book Value Ratio|MetaVia Inc. - Market-to-Book Ratio|NeurAxis, Inc. (NRXS) - Market Value to Book Value Ratio|HSDT - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio PASG|Market-to-Book Ratio Neuphoria Therapeutics|NERV (Minerva Neurosciences Corp) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio ATHA|Addex Therapeutics (ADXN) - Market Value to Book Value Ratio|Market Value to Book Value ALZN (alzamend.com)|CYCN: Market Value to Book Value Ratio|Protagenic Therapeutics Inc. - Market-to-Book Ratio|Pasithea (KTTA) - Market Value to Book Value Ratio|CRGT - Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ATXI|Market-to-Book Ratio brainstorm-cell.com|CARA (Cara Therapeutics) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio CHRO|Eliem Therapeutics (ELYM) - Market Value to Book Value Ratio|Market Value to Book Value ITCI (intracellulartherapies.com)|LBPH: Market Value to Book Value Ratio|Market-to-Book Ratio marinuspharma.com MRNS|Market Capitalization to Book Value Ratio NKGN|NRBO - Market Value to Equity Ratio|Market Capitalization to Book Value Ratio SAGE|SNPX (Synaptogenix, Inc) - Market-to-Book Ratio|Market Value to Book Value Ratio Trevena, Inc. (TRVN)|Capitalization to Book Value Ratio Vigil Neuro|Anew Medical, Inc. - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Cerevel Therapeutics Inc CERE